Neuland Laboratories share news and announcements
NSE: NEULANDLABBSE: 524558Pharmaceuticals & BiotechnologySmall Cap
Last close ₹18,865.00down ₹70.00 (0.37%)BSE ₹18,924.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹18,935.00.
52-week range of traded prices to 23 Oct 2026
₹11,500.00Low, 23 Mar 2026₹24,225.00High, 9 Sep 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹24,204 Cr356th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 5 Aug 2026
- 48.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 12 May 2026
- 12.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.18%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 5 Aug 2026
- 29.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 5 Aug 2026
- 32.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 12 May 2026
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 53,34748.3% delivered
Neuland Laboratories dividends
19 filed, newest first.
May 2025
May 2024
10 May · Dividend
May 2023
11 May · Dividend
May 2022
10 May · Dividend
Jun 2021
7 Jun · Dividend
May 2021
Nov 2020
Oct 2020
Feb 2020
May 2019
May 2016
May 2015
8 May · Dividend
Board of Directors in their meeting held on May 8, 2015 have recommended payment of dividend of 15% at Rs.1.50 per equity share on a face value of Rs.10 each, subject to the approval of members of the company.
May 2014
9 May · Dividend
Board of Directors of the Company at its meeting held on May 09, 2014 have recommended payment of dividend of 30% (including a special dividend of 15%) at Rs.3 per equity share on a face value of Rs.10 each, subject to the approval of members of the Company.
May 2013
10 May · Dividend
Board of Directors of the Company at its meeting held on May 10, 2013 has recommended payment of dividend of Rs. 1.20 per share of a face value of Rs.10 each, subject to the approval of Bankers and shareholders of the Company.
May 2009
22 May · Dividend
Board of Directors in their meeting held today i.e. May 21, 2009:(1)Have proposed a dividend of Rs 3.50 per share on the equity share capital of the company subject to approval of the shareholders in the ensuing Annual General Meeting. (2) Have fixed the book closure from July 15, 2009 to July 18, 2009 (both days inclusive) for the purpose of ensuing Annual General Meeting.(3) Have approved promotion of Mr. D Sucheth Rao as Chief Executive Officer of the company. (4) Have appointed Co-opting of Mr D.Saharsh Rao as additional Director and appointment as Whole Time Director in ensuing Annual General Meeting.